TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04865445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527 550 mg + midazolam
Description: Day 1: 2 mg midazolam Day 3: 550 mg AT-527 and 2 mg midazolam in the morning and a second 550 mg AT-527 dose in the evening.~Days 4 to 6: 550 mg AT-527 administered twice daily (BID) Day 7: 550 mg AT-527 and 2 mg midazolam in the morning and a second 550 mg AT-527 dose in the evening.~Other Names: AT-527 is also know as R07496998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527 550 mg + midazolam
Description: Day 1: 2 mg midazolam Day 3: 550 mg AT-527 and 2 mg midazolam (with dosing offset by 2 hrs) in the morning and a second 550 mg AT-527 dose in the evening.~Days 4 to 6: 550 mg AT-527 administered twice daily (BID) Day 7: 550 mg AT-527 and 2 mg midazolam (with dosing offset by 2 hrs) in the morning and a second 550 mg AT-527 dose in the evening.~Other Names: AT-527 is also know as R07496998
Study: NCT05500118

Intervention type: OTHER
Intervention: Patients Decision Aids
Description: Patient Decision Aids (PDAs) are an important way to facilitate making decision by patients, helping patients make specific and prudent choices by providing information about treatment options and corresponding outcomes, including benefits and risks, related to their health status. The purpose of PDAs is to encourage patients to participate in decision-making. It makes it easier for patients and doctors to discuss treatment options. It effectively promotes communication between patients and doctors. It can help patients combine their own needs and professional advice to make better, more individualized diagnosis and treatment options.
Study: NCT00084032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured treatment interruption
Description: Treatment interruption schedule is dependent on the Arm in which participants are enrolled in Step 2

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured treatment interruption
Description: Treatment interruption schedule is dependent on the Arm in which participants are enrolled in Step 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral regimen
Description: Participants will take any combination of FDA-approved ARV medications prescribed by their physician

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral regimen
Description: Participants will take any combination of FDA-approved ARV medications prescribed by their physician
Study: NCT04866732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Cardiac Health Program
Description: The investigators anticipate that the physical activity program will include the following components: a) physical activity component - the investigators propose an incremental physical activity component whereby participants will gradually increase their physical activity ( duration of walk) from baseline to the end of the study; b) weekly informational sessions on various topics related to Cardiovascular disease risk factors prevention; c) daily diary, which will be used to document record about any barriers for completing various components of the intervention; d) problem-solving sessions whereby participants will meet once a week with the investigators to talk about the barriers and facilitators of their weekly activity and any adherence issues.
Study: NCT06483347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab
Description: This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab
Description: This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab
Description: This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks.
Study: NCT05206292

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Sulfitest
Description: Urine strip to detect the presence of sulfites in urine. Immediate result.
Study: NCT04943484

Intervention type: PROCEDURE
Intervention: imaging fluorescence NIR/ICG
Description: Preoperative upper GI endoscopy (UGE) UGE with submucosal injection of 2ml of ICG 0.125mg/ml solution to four peritumoral sites 15-20 hours before surgery Surgery D2 Distal gastrectomy with dissection of 1, 3, 4sb, 4sd, 5, 6, 7, 8a, 9, 11p, 12a lymph node stations (LNS) D2 Total gastrectomy with dissection of 1, 2, 3, 4sa, 4sb, 4d, 5, 6, 7, 8a, 9, 11p, 11d, 12a LNS Intraoperative NIR/ICG technology, change of surgical conduct (CSC) A visualization of the operative field (OF) with NIR/ICG technology is performed at the beginning of surgery and before to dissect each LNS. Subsequently, surgery is performed with the naked eye.~At the end, a visualization of the OF is performed using NIR/ICG technology to verify whether residual lymph nodes in each D2 nodal station exist. CSC is defined as the occurring of the following situation: in case of persistence of nodal fluorescence in D2 nodal stations, the completion of the dissection of the residual nodal fluorescent structures.
Study: NCT04063514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound
Description: With focused ultrasound, there is an expected accentuation of local perfusion and potential temporary opening of the blood brain barrier with the aim is to provide better delivery of therapeutic agents including medication, particulates and cellular elements for treatment of neoplastic, inflammatory and degenerative brain diseases. The present study seeks to investigate differences in perfusion between areas treated and untreated by this modality in order to further explore its use in clinical application for the treatment of brain disease.
Study: NCT05462405

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: In the setting phase subjects will be in recumbent position. A microneurography needle (0.2mm diameter isolated Tungsten micro-electrode) will be placed under the skin. An identical (not isolated) reference needle tip will be inserted within 2 cm of the first electrode. These are connected to a recording system (ADInstruments PowerLab). Once sympathetic activity can be measured using the needles, a sympathetic specific test will be used to calibrate the measurement and recording system. In the testing phase sequential pacing and CNT delivery will be programmed for a few minutes, the whole procedure expected to last less than 2 hours.
Study: NCT05816057

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: semaglutide injection
Description: The subject will receive either a dose semaglutide once weekly (subcutaneous (s.c.) injection). The initial dose of 0.25 mg is s.c. once weekly, and the dose is increased to 0.5 mg after 4 weeks of administration, and the dose is increased to 1 mg after 4 weeks of 0.5 mg administration, and the dose is continued at a stable dose of 1 mg for 24 weeks.Treatment duration 32 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: semaglutide injection
Description: The subject will receive either a dose semaglutide once weekly (subcutaneous (s.c.) injection). The initial dose of 0.25 mg is s.c. once weekly, and the dose is increased to 0.5 mg after 4 weeks of administration, and the dose is increased to 1 mg after 4 weeks of 0.5 mg administration, and the dose is continued at a stable dose of 1 mg for 24 weeks.Treatment duration 32 weeks.
Study: NCT04896411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternative phrasing for no code
Description: This intervention will use the alternative phrase noted in the literature when discussing code status. This will be the only intervention, and all other aspects of trial participation will be collection of data

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care for no code
Description: This intervention will use the standard of care phrase noted in the literature when discussing code status. This will be the only intervention, and all other aspects of trial participation will be collection of data
Study: NCT04527445

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduced radiation fluoroscopy
Description: See previous information about each arm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional fluoroscopy
Description: See previous information about each arm
Study: NCT06405217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Thyroid Stimulating Hormone
Description: Recombinant human thyroid stimulating hormone injection: 0.9mg/1.0mL/piece; intramuscular injection; once a day for two consecutive days
Study: NCT05636904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prostaglandin F2a analogue in vehicle solution high dose
Description: Topical treatment for 24 weeks
Study: NCT04746911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ-151 cream 0.3%
Description: ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks
Study: NCT05636904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prostaglandin F2a analogue in vehicle solution low dose
Description: Topical treatment for 24 weeks
Study: NCT05241041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group counseling
Description: Group counseling with positive psychology and motivational interviewing was undertaken once per week for 6 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: group counseling
Description: Group counseling with positive psychology and motivational interviewing was undertaken once per week for 6 weeks.
Study: NCT04941521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide 2 mg [Bydureon]
Description: Exenatide will be purchased commercially as Bydureon® for subcutaneous (SC) injection and administered at a dose of 2 mg once a week for a total of 6 weeks. Each single-dose, dual-chamber pen contains 0.65 mg of diluent and 2 mg of exenatide, which remains isolated until mixed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drug Counseling
Description: Once weekly drug counseling sessions for cocaine use with trained masters-level therapists.
Study: NCT05854017

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Theanine for stress relief formulation
Description: Theanine for stress relief formulation tablet

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT05636904

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: active ingredient-free vehicle solution to DLQ01
Description: Topical treatment for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil 5% Topical Solution
Description: Topical treatment for 24 weeks
Study: NCT05241041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: auricular acupressure
Description: Auricular acupressure using acupellets was performed for 6 weeks continuously.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: auricular acupressure
Description: Auricular acupressure using acupellets was performed for 6 weeks continuously.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo acupressure
Description: Placebo acupellets were prepared without metal projections, and placed on both sides in the same areas of the ear as the active condition.
Study: NCT06215053

Intervention type: OTHER
Group type: OTHER
Intervention: erector spine plane block
Description: After anesthesia and surgical procedures, bilateral ESP block will be applied under ultrasonography guidance from the midline 3 cm lateral from the T10 level. After cleaning the area with povidone-iodine before the block, the T10 transverse protrusion will be determined using a linear ultrasound probe. Local anesthetic will be applied between the transverse process and the erector spinae muscle with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection with physiological saline without local anesthesia. After the location of the needle is confirmed, 20 ml of LA and saline mixture will be applied and the same process will be repeated in the contralateral side. Of the total 40 ml LA, 20 ml will consist of bupivacaine 0.5% (MARCAİNE), 10 ml will consist of lidocaine 2% (Aritmal), and 10 ml will consist of physiological saline.

Intervention type: OTHER
Group type: OTHER
Intervention: erector spine plane block
Description: After anesthesia and surgical procedures, bilateral ESP block will be applied under ultrasonography guidance from the midline 3 cm lateral from the T10 level. After cleaning the area with povidone-iodine before the block, the T10 transverse protrusion will be determined using a linear ultrasound probe. Local anesthetic will be applied between the transverse process and the erector spinae muscle with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection with physiological saline without local anesthesia. After the location of the needle is confirmed, 20 ml of LA and saline mixture will be applied and the same process will be repeated in the contralateral side. Of the total 40 ml LA, 20 ml will consist of bupivacaine 0.5% (MARCAİNE), 10 ml will consist of lidocaine 2% (Aritmal), and 10 ml will consist of physiological saline.
Study: NCT04967742

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-612
Description: UB-612 includes a designer S1-RBD-sFc fusion protein formulated with designer Th and CTL epitope peptides selected from immunodominant M, S2 and N regions known to bind to human MHC I and II.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-612
Description: UB-612 includes a designer S1-RBD-sFc fusion protein formulated with designer Th and CTL epitope peptides selected from immunodominant M, S2 and N regions known to bind to human MHC I and II.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-612
Description: UB-612 includes a designer S1-RBD-sFc fusion protein formulated with designer Th and CTL epitope peptides selected from immunodominant M, S2 and N regions known to bind to human MHC I and II.
Study: NCT06006611

Intervention type: DRUG
Intervention: Azvudine
Description: Received antiviral treatment with azvudine
Study: NCT06383793

Intervention type: PROCEDURE
Intervention: overlap
Description: Π

Intervention type: PROCEDURE
Intervention: overlap
Description: Π
Study: NCT04630964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: psilocybin 25 mg Single Oral Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niacin
Description: niacin 100mg Single Oral Dose
Study: NCT05635370

Intervention type: DRUG
Intervention: Pentoxifylline
Description: Pentoxifylline claim is used as the exposure group.

Intervention type: DRUG
Intervention: Cilostazol
Description: Cilostazol claim is used as the reference group.
Study: NCT04860063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Description: Participants randomly assigned to the intervention group will be provided with Berberine 500 mg administrated per os three times a day for six months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomly assigned to the Placebo group will be provided with placebo administrated per os three times a day for six months
Study: NCT04600778

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavosonstat 5 mg
Description: Cavosonstat (low dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavosonstat 10 mg
Description: Cavosonstat (medium dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavosonstat 25 mg
Description: Cavosonstat (high dose)
Study: NCT04303325

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine
Description: All depression patients undergoing breast cancer operation will be to the treatment intervention with general anesthesia as an adjunct to esketamine 0.2mg/kg.
Study: NCT06320808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FDA template PMI
Description: Intervention is an information format viewed by participants. The patient medication information format was designed according to a proposed FDA template, which provides information about safe and effective use of a medication. No drug or device is included as part of this intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Critical PMI
Description: Intervention is an information format viewed by participants. The patient medication information format was designed according to a proposed FDA template and modified, according to decision science principles, to include benefit information, which provides information about safe and effective use of a medication. No drug or device is included as part of this intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Information
Description: The intervention is an information format viewed by participants. This patient medication information format is the current standard of care patient medication information that is included with the drug. No drug or device is included as part of this intervention.
Study: NCT04303325

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: All depression patients undergoing breast cancer operation will be to the treatment intervention with general anesthesia as an adjunct to saline.
Study: NCT06363474

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decompressive Craniectomy
Description: Patients allocated to this arm will undergo decompressive craniectomy, which involves the surgical removal of a section of the skull (bone flap). This procedure is performed to alleviate intracranial pressure (ICP) by providing additional space for the swollen brain to expand. The surgery will be performed by a single surgical team under general anesthesia. After the procedure, patients will be closely monitored for various parameters including duration on mechanical ventilation, duration of ICU stay, duration of hospital stay, and Glasgow Outcome Scale (GOS) at the time of discharge.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cisternostomy
Description: Patients allocated to this arm will undergo cisternostomy, a microsurgical technique used in neurosurgery. Cisternostomy involves the creation of an additional space for cerebrospinal fluid (CSF) circulation to alleviate brain edema and lower intracranial pressure (ICP). The surgery will be performed by the same surgical team under general anesthesia. Following the procedure, patients will be monitored for various parameters including duration on mechanical ventilation, duration of ICU stay, duration of hospital stay, and Glasgow Outcome Scale (GOS) at the time of discharge.
Study: NCT05435313

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAIC
Description: After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: 3mg, qd, po, 21 days for a cycle, Suspend medication on the day of HAIC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg, ivgtt, d1, 21 days for a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: 2 mg/m2, hepatic artery infusion for 15 min, d1, 4-6 Cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2, hepatic artery infusion for 2 h, d1, 4-6 Cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 120mg/m2, hepatic artery perfusion for 30-90min, d1, 4-6 Cycles
Study: NCT05177939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPB-01
Description: NPB-01 will be administered for the treatment of autoimmune encephalitis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPB-01-ME
Description: NPB-01-ME will be administered for the treatment of autoimmune encephalitis
Study: NCT06052085

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain Neuroscience Education
Description: Four sessions of Pain Neuroscience Education will be applied. The neurophysiology of pain and the ability of the nervous system to modulate the experience of pain will be explained to the patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biomedical Pain Education
Description: 4 sessions of Biomedical Pain Education will be applied in 6 weeks. Pain will be explained to the patient from a biological point of view.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physiotherapy Program
Description: Soft tissue mobilization will be applied to the upper extremity twice a week for 6 weeks. Upper extremity exercises including breathing, warming, stretching and strengthening will be performed twice a week for 6 weeks.